Biohaven, a commercial-stage biopharmaceutical company, agreed to acquire Channel Biosciences from Knopp Biosciences, a Pittsburgh-based drug discovery and development company, for up to $1.24bn. "With this transaction, we have added one of the most innovative and exciting therapeutic targets for epilepsy to Biohaven's portfolio. This technology platform is poised to deliver new treatment options for patients suffering from epilepsy and, if ultimately approved, will be synergistic with our existing commercial sales force already calling upon neurologists who also may treat patients with seizures. We are excited to welcome Mike, Steven and members of the Kv7 team into the Biohaven family and look forward to working with them to accelerate this platform to benefit patients," Vlad Coric, Biohaven CEO and Chairman of the Board.